IMPACT OF DELAY TO TREATMENT UPON SURVIVAL IN 1067 PATIENTS WITH BREAST-CANCER
M. G. Rabinovich(Universidad de Buenos Aires), RA ESTEVEZ(Universidad de Buenos Aires), R Rodríguez(Universidad de Buenos Aires), MA CUEVAS(Universidad de Buenos Aires), JE PEREZ(Universidad de Buenos Aires), R. Contreras Chacon(Universidad de Buenos Aires), J. A. Lacava(Universidad de Buenos Aires), C. Vallejo(Universidad de Buenos Aires), B. A. Leone(Universidad de Buenos Aires), AO Romero(Universidad de Buenos Aires), MR Machiavelli(Universidad de Buenos Aires), E. Mickiewicz(University of Chicago)
Cited by 10
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318
LEVAMISOLE IN ADVANCED HUMAN BREAST CANCER
|The Lancet|1976|159